Search Results

The IPGTFL-02 is intended for incision, excision, resection, ablation, coagulation, hemostasis, and vaporization of soft tissue, with or without an endoscope, in the following indications: urology, lithotripsy, gastroenterological surgery and gynecological surgery.

Urology:

• Ablation of Benign Prostatic Hyperplasia (Hypertrophy) [BPH]
• Laser Resection of the Prostate (LRP)
• Laser Enucleation of the Prostate (LEP)
• Laser Ablation of the Prostate (LAP)
• Transurethral Incision of the Prostate (TUIP)
• Condylomas
• Urethral strictures
• Lesions of external genitalia
• Bladder neck incisions (BNI)
• Ablation and resection of bladder tumors, urethral tumors, and ureteral tumors
• Endoscopic fragmentation of urethral, ureteral, bladder, and renal calculi with integrated detection of calculi and mucosal tissue by StoneSense module that reduces exposure of mucosal tissue to laser energy and reduces resulting damage to mucosal tissue
• Treatment of distal impacted fragments remaining in the ureters following lithotripsy

Lithotripsy and Percutaneous Urinary Lithotripsy:

• Endoscopic fragmentation of urethral, ureteral, bladder and renal calculi including cystine, calcium oxalate, monohydrate and calcium oxalate dihydrate stones.
• Endoscopic fragmentation of renal calculi
• Treatment of distal impacted fragments of steinstrasse when guide wire cannot be passed.

Gastroenterology:

Open and endoscopic gastroenterology surgery (incision, excision, resection, ablation, vaporization, coagulation and hemostasis) including:

• Appendectomy
• Angiodysplasia
• Polyps
• Colorectal cancer
• Biopsy
• Telangiectasias
• Gall Bladder calculi
• Telangiectasias of the Osler-Weber-Renu disease
• Biliary/Bile duct calculi
• Vascular Malformation
• Ulcers
• Gastritis
• Gastric ulcers
• Esophagitis
• Duodenal ulcers
• Esophageal ulcers
• Non Bleeding Ulcers
• Varices
• Pancreatitis
• Colitis
• Hemorrhoids
• Mallory-Weiss tear
• Cholecystectomy
• Gastric Erosions
• Benign and Malignant Neoplasm

Gynecology:

Open and laparoscopic gynecological surgery (incision, excision, resection, ablation, vaporization, coagulation and hemostasis) of soft tissue.

IPGTFL-02 is a desktop, portable thulium laser source and controller used with specific surgical fibers (single-use & reusable) for incision, excision, resection, ablation, coagulation, hemostasis, and vaporization of soft tissue, with or without an endoscope, in the following indications: urology, lithotripsy, gastroenterological surgery and gynecological surgery.

The laser system generates non-ionizing radiation which is transferred to the relevant anatomical treatment site through surgical fibers that serve as the delivery vehicle from the laser energy generator to the treatment site.

The laser system includes a universal, three-pedal footswitch that can operate in wired and wireless mode for hands-free control. The system can utilize a customer-supplied, medical grade external surgical monitor to display endoscope video as well as the device's user interface.

The laser system's front panel includes a surgical fiber connection port and a touchscreen with a user interface. The rear panel includes electrical and interface cable ports. The laser system may be placed on an optional, mobile cart. The system can utilize an auxiliary video monitor to display operating parameters.

The laser system can operate at a maximum power output of 60 watts in CW, regular and advanced Pulsed modes with a maximum frequency output of 2400 Hz and a maximum pulse energy of 6 Joules.

The laser system must be operated with the IPG Medical Surgical Fibers. The surgical fibers are flexible optical fibers that deliver the laser energy to the target tissue. The surgical fibers are the only patient-contacting components of the IPGTFL-02.

The purpose of this 510(k) is to add an optional module called StoneSense for lithotripsy procedures. During these procedures it is possible that the fiber tip loses contact or quasi-contact with the stone which is undesirable. The module is designed to detect if the object in contact or quasi-contact with the distal fiber tip is "Stone" or "Not Stone". If Stone is not detected, the system will not allow emission of the laser. The addition of Stone sense will add an indication for the device.

Also, three advanced power modes have been added:

• Fragmentation Pulse - Special pulse shape, optimized for stone ablation into large fragments.
• Minimal Carbonization Pulse - Special pulse shape for soft tissues vaporization, incision and excision with minimization of tissue carbonization.
• Enucleation Pulse - Special pulse shape, developed for enucleation procedure to maximize thermo-mechanical separation of adenomic tissue and capsule with simultaneous strong hemostasis effect.

This document provides a summary of the IPGTFL-02 device, focusing on its StoneSense module and new advanced power modes. Here's a breakdown of the requested information based on the provided text:

Acceptance Criteria and Device Performance Study for IPGTFL-02

The IPGTFL-02 is a thulium fiber laser system with added features, including the StoneSense module for lithotripsy procedures and three new advanced power modes. The FDA clearance is based on proving substantial equivalence to a predicate device (K232568).

1. Table of Acceptance Criteria and Reported Device Performance

The provided document doesn't explicitly state quantitative acceptance criteria in a dedicated table. However, it describes the purpose and function of the new features, which implicitly sets performance expectations. Based on the description, the following can be inferred:

2. Sample Size and Data Provenance for Test Set

• Test Set for StoneSense Module: "simulated procedure with a known value of 'Stone' or 'Not Stone'".
  • Sample Size: Not specified. The phrase "known value" suggests a controlled experimental setup, but the number of instances or trials is not provided.
  • Data Provenance: Not explicitly stated, but likely laboratory-based (ex-vivo simulation). No country of origin is mentioned. The study is prospective in the sense that the test was conducted specifically to evaluate the device functionality.
• Test Set for New Power Modes: "Ex-vivo testing was completed to compare effects such as fragmentation efficiency, ablation depth, coagulation width and carbonization grade and coagulation of the new power modes to the predicate device."
  • Sample Size: Not specified.
  • Data Provenance: Ex-vivo testing, meaning performed on excised tissue or materials, not in living subjects. No country of origin is mentioned. This is a prospective test.

3. Number and Qualifications of Experts for Ground Truth

• The document does not specify the number or qualifications of experts used to establish ground truth for either the StoneSense module or the new power modes.
  • For StoneSense, the ground truth was based on "known value of 'Stone' or 'Not Stone'," suggesting a predetermined classification in the simulated environment.
  • For the new power modes, "effects such as fragmentation efficiency, ablation depth, coagulation width and carbonization grade" were compared. This likely involved objective measurements rather than direct expert consensus on a subjective interpretation.

4. Adjudication Method for the Test Set

The document does not provide information on any adjudication method (e.g., 2+1, 3+1, none) for the test set. Given the nature of the ex-vivo and simulated testing, it's possible that adjudication in the typical sense of reconciling expert opinions was not performed.

5. Multi Reader Multi Case (MRMC) Comparative Effectiveness Study

There is no mention of a Multi Reader Multi Case (MRMC) comparative effectiveness study being done. The studies described are non-clinical, comparing device performance metrics directly or in simulated environments, not involving human readers/operators in a comparative effectiveness study setting. Therefore, no effect size of human reader improvement with AI vs. without AI assistance is reported.

6. Standalone (Algorithm Only) Performance Study

Yes, a standalone performance study was done for the StoneSense module. The testing involved comparing "StoneSense determination of 'Stone' or 'Not Stone' during a simulated procedure with a known value of 'Stone' or 'Not Stone'." This evaluates the algorithm's ability to classify objects without human intervention in the classification process.

7. Type of Ground Truth Used for Test Set

• StoneSense Module: "Known value of 'Stone' or 'Not Stone'". This represents an objective or predetermined ground truth established within the simulated testing environment. It is not expert consensus, pathology, or outcomes data in the clinical sense.
• New Power Modes: The ground truth was based on objective measurements of characteristics like "fragmentation efficiency, ablation depth, coagulation width, and carbonization grade." This is a quantitative, measured ground truth, effectively comparing the device's output to defined physical properties.

8. Sample Size for the Training Set

The document does not specify the sample size used for the training set for any of the new features, including the StoneSense module or the advanced power modes.

9. How Ground Truth for the Training Set was Established

The document does not describe how the ground truth for any training set was established. Given the nature of the device (a laser system with a detection module and optimized pulses), it's possible that the "training" involved various experimental configurations and data collection to develop the algorithms for StoneSense and the pulse shapes, rather than a traditional medical image or clinical data training set with externally validated ground truth like pathology reports.

Ask a specific question about this device